New biosimilar for RA to save millions September 07, 2016 By Christine Blank FDA’s approval of a new biosimilar—the third FDA-approved biosimilar—stands to save the US healthcare system millions of dollars. Abuse-deterrent opioid pain drug approved August 29, 2016 By Christine Blank FDA recently approved the only oxycodone with oral abuse-deterrent features. Cheaper generic EpiPen doesn't quiet critics August 29, 2016 By Christine Blank Despite offering a generic version of its EpiPen, Mylan has been unable to curb the backlash that began in late August over the cost of its epinephrine injection. Health costs rise for diabetes patients Healthcare spending for people with diabetes rose nearly 6% in 2014, according to a new study. Find out what contributed to the rise. Diabetes increases risk of heart attack by half UK study: Diabetes increases risk of heart attack death. Here are the surprising details. EpiPen discounts offered after pricing flap August 24, 2016 By Christine Blank After protests by patients, parents and Congressional representatives, Mylan said it would offer discounts on its epinephrine EpiPen Auto-Injector treatment to stop allergic reactions. Game-changing depression drug on horizon August 24, 2016 By Christine Blank FDA recently granted Breakthrough Therapy Designation for esketamine (Janssen Research & Development), an investigational medication to treat major depressive disorder with imminent risk for suicide. Are PCSK9 inhibitors too pricey? August 18, 2016 By Christine Blank PCSK9 inhibitors such as alirocumab (Praluent, Sanofi) and evolocumab (Repatha, Amgen) are priced too high to benefit the US healthcare system, according to a new study. New drug approved for chemotherapy nausea August 17, 2016 By Christine Blank FDA recently approved granisetron (Sustol, Heron Therapeutics) extended-release injection to prevent nausea and vomiting associated with repeat courses of chemotherapy. AbbVie hep C drug combo enters market August 14, 2016 By Christine Blank In an era when legislators, pharmacy benefit managers and others continue to protest the high cost of hepatitis C drugs, new drugs to treat the disease are welcomed. FDA recently approved ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets (Viekira XR, AbbVie) to treat patients with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection, including those with cirrhosis. AbbVie already markets Viekira Pak, which competes with Harvoni and Sovaldi (Gilead Sciences).